Skip to main content
Clinical Trials/NCT03473522
NCT03473522
Completed
Phase 2

Effects of Transcranial Direct Current Stimulation Combined With Therapeutic Exercises in Patients With Parkinson's Disease: Randomized Clinical Trial

Alessandra Tanuri Magalhães1 site in 1 country30 target enrollmentFebruary 1, 2018

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Alessandra Tanuri Magalhães
Enrollment
30
Locations
1
Primary Endpoint
Change From balance
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Parkinson's disease is a progressive, degenerative neurological disease associated with profound changes in the quality of life of its survivors. Therapeutic exercises are widely employed in the attempt to delay or minimize disease progression, characterized by significant motor and sensory deficits. Recent evidence has demonstrated the potential use of transcranial direct current stimulation (TDCs) as a complement to therapeutic exercises. However, few studies have investigated the effects of TDCs combined with therapeutic exercises in patients with Parkinson's disease. This study aims to investigate the effect of TDCs combined with therapeutic exercises in people with Parkinson's disease. Thirty patients will be randomized into two distinct groups to receive either TDCs(anodal) + therapeutic exercises or TDCs (sham) + therapeutic exercises for 24 sessions over a five-week period. The primary clinical outcome (balance) and secondary outcomes (functional capacity, quality of life and perception of overall effect) will be collected before treatment after two and five weeks at month 3 and month 6 after randomization. The data will be collected by a blind examiner to the treatment allocation.

Detailed Description

In this study, a randomized, double-blind, placebo-controlled experimental design will be used. The 30 participants will be randomized into two groups: (1) TDCs(anodal) + therapeutic exercises and (2) TDCs (sham) + therapeutic exercises. The treatment will be performed for 8 weeks, with three sessions per week, totaling 24 sessions of electrostimulation and therapeutic exercises. The primary variable (balance), secondary outcomes and other outcomes will be assessed before and after treatment. Follow-up of patients will be conducted at 8, 12 and 24 weeks after randomization. All evaluations will be performed by a single researcher who, like the patients, will not know which stimulation group will be participating. Patients diagnosed with Parkinson's who seek treatment at the Clinical School of Physiotherapy of the Federal University of Piauí will receive detailed instructions on the present study. The physiotherapist responsible for evaluations will explain the objectives of the study, possible treatments, eligibility criteria and potential risks arising from the application of brain stimulation and therapeutic exercises. Patients who agree to the conditions and sign the consent form may participate in the study. Participants who meet the eligibility criteria will be included in the study.

Registry
clinicaltrials.gov
Start Date
February 1, 2018
End Date
January 15, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Alessandra Tanuri Magalhães
Responsible Party
Sponsor Investigator
Principal Investigator

Alessandra Tanuri Magalhães

Full Professor of Physical Therapy Department

Universidade Federal do Piauí

Eligibility Criteria

Inclusion Criteria

  • medical diagnosis of idiopathic Parkinson's disease present for at least 12 months,
  • spontaneous demand for treatment,
  • in clinical follow-up and pharmacological treatment by a responsible physician,
  • Parkinson's classification of 1.5-3 according to the Hoehn and Yahr scale,
  • absence of cardiovascular diseases and musculoskeletal,
  • signing of the free and informed consent form.

Exclusion Criteria

  • Use any associated orthopedic device to aid gait or balance control,
  • signs of severe dementia (evaluated by the Mini-Mental State Examination - MMSE),
  • diagnosis of other neurological disorders (including those of central and peripheral nature)
  • previous treatment with tDCS,
  • medical diagnosis of psychiatric illnesses with the use of centrally acting medications (depressants)
  • the use of pacemakers or other implanted devices.

Outcomes

Primary Outcomes

Change From balance

Time Frame: 8 weeks after randomization

Balance will be evaluated using a force plate to record center of pressure displacement (COP) in antero-posterior (AP) and Mediolateral (ML) axes in centimeters. Other variables such as area (cm²), speed AP and ML(cm/s), frequency (Hz) and Entropy (no unit) will be derived from COP displacement.

Secondary Outcomes

  • Change From Parkinson Disease Quality of Life(8 weeks, 3 and 6 months after randomization)
  • Change From balance(3 and 6 months after randomization)
  • Change in the perception scale of the overall effect(8 weeks, 3 and 6 months after randomization)
  • Maximal Isometric Voluntary Contraction(8 weeks, 3 and 6 months after randomization)
  • Change From Unified Parkinson´s Disease Rating Scale(8 weeks, 3 and 6 months after randomization)
  • Tampa Scale for Kinesiophobia (TSK)(8 weeks, 3 and 6 months after randomization)

Study Sites (1)

Loading locations...

Similar Trials